ArticleInvestigative ophthalmology & visual science2026
Gut Microbial Metabolite Indole-3-Acetic Acid Exerts Protective Effects by Regulating Orbital Fibroblast Fibrosis in Thyroid Eye Disease.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To profile the gut microbiota and plasma metabolites of patients with thyroid eye disease (TED) and to investigate the potential regulatory role and mechanisms of the tryptophan metabolite indole-3-acetic acid (IAA) in this disorder. Methods: The clinical study enrolled 70 patients with TED and 76 controls. Fecal and plasma samples were collected for 16S rRNA sequencing and metabolomic analyses, respectively. For the in vitro study, orbital fibroblasts (OFs) were treated with transforming growth factor beta 1 (TGF-β1) to establish a fibrosis model and with adipogenic differentiation medium to establish an adipogenic differentiation model. The effects of IAA on cell viability, migration, fibrosis, and adipogenic differentiation were assessed. The molecular mechanism by which IAA regulates OF fibrosis was explored using transcriptome sequencing and in vitro experiments. Results: Compared with controls, patients with TED exhibited gut microbiota dysbiosis and disrupted plasma tryptophan metabolism. Moreover, IAA levels were significantly reduced and were negatively correlated with proptosis and serum thyrotropin receptor antibody (TRAb) levels. For the in vitro study, IAA inhibited OF migration, fibrotic phenotype, and adipogenic differentiation. Regarding its anti-fibrotic effect, IAA activated aryl hydrocarbon receptor (AHR) signaling and significantly reduced TGF-β1-induced phosphorylation of Smad2/3 proteins. Administration of the AHR antagonist CH-223191 attenuated the activation of AHR signaling in OFs and reduced the inhibitory effect of IAA on TGF-β1-induced Smad2/3 phosphorylation and fibrotic protein expression. Conclusions: Patients with TED exhibit gut microbiota dysbiosis and disrupted plasma tryptophan metabolism. The tryptophan metabolite IAA alleviates OF fibrosis via AHR signaling, suggesting a potential protective role in treating TED.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.